Agreement Re. SECTION 13.3 The Employer and the union shall discuss the extent to which it is possible to keep records necessary to support the determination of longevity eligibility and status. In the interim, the burden of establishing eligibility and placement shall be on the employee. APPENDIX F SIDE LETTER RE: ACADEMIC WORK YEAR FOR TEACHING FACULTY When there are not a sufficient number of class days to meet Board policy, a college may reschedule no more than two Monday holidays to days other than the state-designated day in order to balance the class schedule. No attempt shall be made to reschedule a faculty holiday to a Friday for the sole purpose of having faculty members not present on this particular day. APPENDIX G
Agreement Re. Opener .01 This Agreement may be amended by mutual consent.
Agreement Re. SERIES A PREFERRED SHARES. The Principal Shareholders shall have executed an Agreement re: Series A Preferred Shares, in the form of Schedule 5.03 (m) attached hereto, stating their promises (A) not to convert any of the AVTX Series A Preferred Shares until the registration statement referenced in Section 5.01 (d) with respect to the Operating Sub common stock becomes effective; and (B) to execute and deliver to the Investors at the Closing an irrevocable voting proxy, to be dated on the date of conversion and to be effective for a period of one-year thereafter, with respect to the shares of AVTX common stock issued to the Principal Shareholders upon conversion of their Series A Preferred Shares.
Agreement Re. Non Exclusive Permit To Construct Temporary Earth Retention System And Temporary Support of Subsurface Construction (Fan Pier Project, Building A and Building B, Courthouse Way) to be entered into by and between the City of Boston and. Fifty Northern Avenue LLC and Eleven Fan Pier Boulevard LLC.
Agreement Re. Exercise of Stock Warrant Complete blood counts will be obtained pre-dose, 1 hour post-dose, and then at 2, 4, 6, 12 and 24, 48 and 72 hours post dosing as well as on Day 5,7,10, 14, 21 and 28. These time points will also be utilized for pharmacokinetic sampling. A bone marrow aspirate will be obtained on Day 1 post dose. When a dose is reached at which evidence of pharmacodynamic effect (defined as a X% increase in neutrophils, X % increase in platelet count relative to the pretreatment value) is observed in 2/3 actively treated subjects dosing at that level will be extended to include a further four subjects (3/1 active/placebo). If the efficacy is confirmed one further dose cohort of 6 subjects (4/2 active/placebo) will be enrolled to provide further confirmation of pharmacodynamic effect. If the pharmacodynamic effect is only observed at the highest planned dose a further dose increase will be considered, assuming that no evidence of toxicity has been observed. If a safety /tolerability event that is possibly or probably related to study medication occurs in a single actively treated subject at any dose four further subjects (3/1 active/placebo) will be enrolled at that dose to determine if a dose limiting toxicity has been identified. Excessive thrombocytosis will be managed by administration of anti-platelet agent and if necessary by pheresis. EFFICACY ENDPOINTS Peripheral blood neutrophil, platelet, rbc, reticulocyte and neutrophil counts Peripheral blood CD34+ cells SAFETY ENDPOINTS Peripheral blood neutrophil, platelet, rbc, reticulocyte and neutrophil counts Peripheral blood CD34+ cells Bone Marrow Aspirate (bone marrow morphology and megakaryocte evaluation) Complete blood counts will be obtained pre-dose, 1 hour post-dose, and then at 2, 4, 6, 12 and 24, 48 and 72 hours post dosing as well as on Day 5,7,10, 14, 21 and 28. Agreement Re: Exercise of Stock Warrant EXPLORATORY ENDPOINTS Adverse events Routine safety laboratory tests Platelet aggregation Multipotential colony forming potential in vitro PHARMACOKINETIC Blood samples will be taken for measurement of drug EVALUATION levels pre and post-dose, 5 minutes, 15 minutes, 30 minutes, 1, 2, 4, 6,12, 24, 48, and 72 hours post dosing. Compound levels will be measured using either a cell based bioassay or by ELISA and Cmax, Tmax, AUC and t1/2 will be evaluated. PLANNED SAMPLE SIZE Sample size is based on feasibility. No formal statistical calculations have been performed. It is anticipated that up...
Agreement Re. Joint Use of Poles and Maintenance of Transmission Lines, Substations, Et Cetera, dated January 1, 1950, by and between The Cedar Rapids and Iowa City Railway Company and Iowa Electric Light and Power Company
Agreement Re. Reletting of First Floor Space as described on Exhibit “A-7” shall be added to the Principal Lease Provisions and shall read as follows:
Agreement Re. Future Conduct thereof and have fully and finally performed, in every regard, all their respective obligations and requirements thereunder.
Agreement Re. CLAIMS. Unless required by law to do so, Hewexx xxxll not, directly or indirectly, assist or otherwise participate with any other person or entity in asserting any claims that any such other person or entity now or hereafter may have against the Company or any of its officers, directors or employees.
Agreement Re. RamdiskNT, dated 2/1/2003, between Kodak and Cenatek.
